|
|
Article: Sciele Pharma and Addrenex Announce Submission of sNDA to FDA for Clonicel to Treat ADHD.
- Article from:
- Business Wire
- Article date:
- October 1, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ATLANTA -- Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD). In multi-center, placebo-controlled, double-blind, randomized Phase III clinical trials, Clonicel showed statistical significance when used to treat ADHD.
Ed Schutter, President and Chief Operating Officer of Sciele Pharma, said, "We are pleased that Addrenex has filed the sNDA with the FDA. Clonicel is an important product in our pediatric ...
Related newspaper, magazine, and journal articles:
|
|
Article: Addrenex Pharmaceuticals Acquired by Sciele ...
Blood Weekly;
December 3, 2009 ;
700+ words
...Addrenex Pharmaceuticals announces ... acquired by Sciele Pharma, Inc. The ... Pharmaceuticals Addrenex Pharmaceuticals is a focused ... dysregulation. Addrenex Pharmaceuticals is based ... com About Sciele Pharma, Inc. Sciele ...
|
|